期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
B7 homolog 3 in pancreatic cancer
1
作者 Dijana Perovic Marija Dusanovic Pjevic +5 位作者 Vladimir Perovic milka grk Milica Rasic Maja Milickovic Tanja Mijovic Petar Rasic 《World Journal of Gastroenterology》 SCIE CAS 2024年第31期3654-3667,共14页
Despite advances in cancer treatment,pancreatic cancer(PC)remains a disease with high mortality rates and poor survival outcomes.The B7 homolog 3(B7-H3)checkpoint molecule is overexpressed among many malignant tumors,... Despite advances in cancer treatment,pancreatic cancer(PC)remains a disease with high mortality rates and poor survival outcomes.The B7 homolog 3(B7-H3)checkpoint molecule is overexpressed among many malignant tumors,including PC,with low or absent expression in healthy tissues.By modulating various immunological and nonimmunological molecular mechanisms,B7-H3 may influence the progression of PC.However,the impact of B7-H3 on the survival of patients with PC remains a subject of debate.Still,most available scientific data recognize this molecule as a suppressive factor to antitumor immunity in PC.Furthermore,it has been demonstrated that B7-H3 stimulates the migration,invasion,and metastasis of PC cells,and enhances resistance to chemotherapy.In preclinical models of PC,B7-H3-targeting monoclonal antibodies have exerted profound antitumor effects by increasing natural killer cell-mediated antibodydependent cellular cytotoxicity and delivering radioisotopes and cytotoxic drugs to the tumor site.Finally,PC treatment with B7-H3-targeting antibody-drug conjugates and chimeric antigen receptor T cells is being tested in clinical studies.This review provides a comprehensive analysis of all PC-related studies in the context of B7-H3 and points to deficiencies in the current data that should be overcome by future research. 展开更多
关键词 B7 homolog 3 Pancreatic cancer PROGNOSIS Signaling pathways IMMUNOTHERAPY
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部